NEW YORK (GenomeWeb) - Veracyte today announced after the close of the market that revenues for its first quarter rose 50 percent on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended March 31, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased to $11.2 million from $7.5 million a year ago, beating the average Wall Street expectation of $10.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.